Form 4: Pacira BioSciences Director Brege Acquires 1,000 Shares
SEC Form 4 Filing
Director Laura Brege purchased 1,000 shares of Pacira BioSciences (PCRX) common stock at $12.81 per share on August 16, 2024.
Summary
- On August 16, 2024, Laura Brege, a director of Pacira BioSciences, Inc. (PCRX), acquired 1,000 shares of common stock.
- The purchase price was $12.81 per share.
- Following the transaction, Brege directly owns 17,552 shares of Pacira BioSciences.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director purchasing shares is generally a good sign, but the purchase is relatively small and doesn't provide a strong signal.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider transactions are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future performance. This purchase could be interpreted as a positive signal, but should be considered alongside other factors.
Stakeholder Impact
- The purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/16/2024 | Date of transaction: Laura Brege purchased 1,000 shares of Pacira BioSciences common stock. |
| 08/19/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.